Methylprednisolone
- Atc Codes:D07AA01#D10AA02#H02AB04
- CAS Codes:83-43-2
- PHARMGKB ID:83-43-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Urbason; Belgium: Advantan, Medrol; Bulgaria: Medrol, Methylprednisolone; Cyprus: Advantan, Medrol, Methylprednisolone; Czech Republic: Advantan, Medrol; Denmark: Medrol; Estonia: Advantan, Medrol; Finland: Advantan, Medrol, Solomet; France: Medrol; Germany: Advantan, Atopex, Methylprednisolon, Metycortin, Metypred, Metysolon, M-Prednihexal, Predni M, Urbason; Greece: Advantan, Lyo-Drol, Medrol, Metilprednizolon; Hungary: Advantan, Medrol, Metilprednizolon, Metypred; Ireland: Advantan, Medrone; Italy: Advantan, Medrol, Metilbetasone, Metilpre, Supresol, Urbason; Latvia: Advantan, Medrol, Methylprednisolone; Lithuania: Methylprednisolone; Luxembourg: Medrol, Methylprednisolone; Malta: Advantan, Medrone; Netherlands: Medrol; Poland: Advantan, Medrol; Portugal: Advantan, Medrol; Romania: Advantan, Lemod Solu, Medrol; Slovakia: Advantan, Medrol; Slovenia: Advantan, Medrol; Spain: Adventan, Lexxema, Urbason; Sweden: Medrol; UK: Medrone.
North America
Canada: Medrol, Methylprednisolone; USA: A-Methapred, Medrol, Methylprednisolone.
Latin America
Argentina: Cipridanol, Medrol, Metilprednisolona, Totalsolona; Brazil: Advantan, Alergolon, Medrol, Predmetil, Solupren, Unimedrol; Mexico: Advantan, Cryosolona, Medrol, Metilprednisolona, Metisona, Prednilem, Radilem, Solipred.
Asia
Japan: Decacort, Medrol, Melcort, Pridol.
Drug combinations
Methylprednisolone and Lidocaine
Chemistry
Methylprednisolone: C~22~H~30~O~5~. Mw: 374.47. (1) Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-; (2) 11β,17,21-Trihydroxy-6α-methylpregna-1,4-diene-3,20-dione. CAS-83-43-2.
Pharmacologic Category
Hormones and Synthetic Substitutes; Adrenals. Systemic Corticosteroid. (ATC-Code: D07AA01; D10AA02; H02AB04).
Mechanism of action
Corticosteroids exert wide array of physiologic effects including modulation of carbohydrate, protein, and lipid metabolism and maintenance of fluid and electrolyte homeostasis. Moreover, cardiovascular, immunologic, musculoskeletal, endocrine, and neurologic physiology are influenced by corticosteroids. Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.
Therapeutic use
Primarily as anti-inflammatory or immunosuppressant agent in treatment of a variety of diseases including those of hematologic, allergic, inflammatory, neoplastic, and autoimmune origin. Prevention and treatment of graft-vs-host disease following allogeneic bone marrow transplantation.
Pregnancy and lactiation implications
Adverse events observed with corticosteroids in animal reproduction studies. Methylprednisolone crosses placenta. Low levels of methylprednisolone excreted in breast milk (use caution).
Unlabeled use
Contraindications
Hypersensitivity to methylprednisolone or any component of the formulation. Viral, fungal, or tubercular skin lesions. Administration of live virus vaccines. Serious infections, except septic shock or tuberculous meningitis. Methylprednisolone formulations containing benzyl alcohol preservative contraindicated in infants. Intramuscular administration contraindicated in idiopathic thrombocytopenia purpura.
Warnings and precautions
Might cause hypercorticism or suppression of hypothalamic-pituitary-adrenal axis, particularly in younger children or in patients receiving high doses for prolonged periods. Withdrawal and discontinuation of corticosteroid should be done slowly and carefully. Prolonged use of corticosteroids may increase incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Corticosteroids should not be used to treat ocular herpes simplex, cerebral malaria or viral hepatitis. Acute myopathy reported with high-dose corticosteroids, usually in neuromuscular transmission disorders. Prolonged treatment with corticosteroids associated with development of Kaposi’s sarcoma (case reports). Might cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes, and pre-existing psychiatric conditions may be exacerbated. Use with caution in heart failure, diabetes mellitus, or gastrointestinal disease (diverticulitis, peptic ulcer, ulcerative colitis). High-dose corticosteroids should not be used for management of head injury. Use with caution in hepatic impairment (including cirrhosis), myasthenia gravis, or following myocardial infarct, in cataracts and/or glaucoma (increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use), in osteoporosis (increased bone loss and osteoporotic fractures), in renal impairment (fluid retention may occur), and in history of seizure disorder (seizures reported with adrenal crisis). Metabolic clearance of corticosteroids increases in hyperthyroid, and decreases in hypothyroid patients. Use cautiously in the elderly. May affect growth velocity in pediatric patients. Withdraw therapy with gradual tapering of dose.